Coiled Therapeutics plc

Coiled Therapeutics plc is a clinical-stage oncology company based in London, United Kingdom. It develops and commercialises clinical-stage oncology therapeutics in the United Kingdom and internationally. Its lead asset, AO-252, is a first-in-class small molecule inhibitor of TACC3 in a Phase I trial for advanced solid tumours, including ovarian and prostate cancer. The company also has a STAT-6 siRNA programme targeting immunology indications such as asthma, fibrosis, eczema, and allergic disease, with plans for assessment towards Phase I clinical trials.